Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis.

PubWeight™: 0.83‹?›

🔗 View Article (PMID 27301245)

Published in BMC Med on June 15, 2016


Alimuddin Zumla1, Martin Rao2, Ernest Dodoo2, Markus Maeurer3,4

Author Affiliations

1: Division of Infection and Immunity, University College London, and NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, UK.
2: F79, Therapeutic Immunology (TIM) division, Department of Laboratory Medicine (LABMED), Karolinska University Hospital Huddinge, 14186, Stockholm, Sweden.
3: F79, Therapeutic Immunology (TIM) division, Department of Laboratory Medicine (LABMED), Karolinska University Hospital Huddinge, 14186, Stockholm, Sweden. markus.maeurer@ki.se.
4: Centre for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge, Stockholm, Sweden. markus.maeurer@ki.se.

Associated clinical trials:

Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | NCT01968109

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer | NCT01727076

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | NCT02460224

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC) | NCT02088112

Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies | NCT02061761

A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Subjects and Patients With Plaque Psoriasis | NCT02195349

Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma | NCT02584829

Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Combination Therapy for Pulmonary Tuberculosis (TB) | NCT01638520

Anti-PD-L1 in Stage IIIA(N2) NSCLC | NCT02572843

A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1) | NCT02588131

Articles cited by this

(truncated to the top 100)

The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94

PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39

An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature (2010) 10.37

Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature (2009) 8.09

Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet (2015) 7.18

Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity (2012) 6.29

The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 5.99

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75

The future of immune checkpoint therapy. Science (2015) 5.59

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44

Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity (2011) 5.43

Statins as a newly recognized type of immunomodulator. Nat Med (2000) 5.00

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol (2015) 4.68

Histone deacetylase inhibitors in cancer therapy. J Clin Oncol (2009) 4.58

Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood (2005) 4.29

Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov (2005) 3.92

Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature (2014) 3.60

Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell (2012) 3.54

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. J Clin Invest (2014) 3.54

Adoptive cell transfer as personalized immunotherapy for human cancer. Science (2015) 3.19

Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS (2004) 3.17

Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Arch Intern Med (2008) 3.10

Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon γ-producing T cells from apoptosis in patients with pulmonary tuberculosis. J Infect Dis (2013) 3.03

Histone deacetylase inhibitors. Adv Cancer Res (2004) 2.93

Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev (2012) 2.82

Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest (2009) 2.75

TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial reactive oxygen species. Cell (2013) 2.71

Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis (2009) 2.66

Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat Immunol (2011) 2.54

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol (2014) 2.39

Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet Respir Med (2015) 2.31

Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS (2009) 2.28

Prednisone as adjunctive therapy in the management of pulmonary tuberculosis. Report of 12 cases and review of the literature. Chest (1995) 2.26

Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol (2013) 2.22

The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res (2005) 2.18

Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med (2006) 2.16

Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med (2008) 2.14

Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect Dis (2013) 2.05

Alteration of serum inflammatory cytokines in active pulmonary tuberculosis following anti-tuberculosis drug therapy. Mol Immunol (2014) 2.01

Longevity loss among cured tuberculosis patients and the potential value of prevention. Int J Tuberc Lung Dis (2014) 1.99

Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med (2014) 1.98

Metformin: from mechanisms of action to therapies. Cell Metab (2014) 1.94

Clinical blockade of PD1 and LAG3--potential mechanisms of action. Nat Rev Immunol (2015) 1.79

Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J Infect Dis (2013) 1.79

Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis (2015) 1.76

Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev (2008) 1.74

IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis. Proc Natl Acad Sci U S A (2008) 1.72

Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle. Cell Metab (2014) 1.72

Immunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and non-immune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculosis starting antiretroviral therapy: a prospective observational cohort study. Lancet Infect Dis (2015) 1.70

Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med (2013) 1.69

Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J Immunol (2008) 1.67

Antimicrobial activity of MHC class I-restricted CD8+ T cells in human tuberculosis. Proc Natl Acad Sci U S A (2000) 1.65

Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir Med (2014) 1.62

Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neuro Oncol (2009) 1.51

Resveratrol (trans-3,5,4'-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol Pharmacol (2007) 1.43

Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review. Lancet Respir Med (2014) 1.42

Metformin as adjunct antituberculosis therapy. Sci Transl Med (2014) 1.40

A high-throughput respirometric assay for mitochondrial biogenesis and toxicity. Anal Biochem (2010) 1.38

Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol (2013) 1.35

Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res (2010) 1.32

Immunosuppression during active tuberculosis is characterized by decreased interferon- gamma production and CD25 expression with elevated forkhead box P3, transforming growth factor- beta , and interleukin-4 mRNA levels. J Infect Dis (2007) 1.30

Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa. Trop Med Int Health (2012) 1.29

Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmacokinet (2000) 1.29

Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. Int J Clin Pract (2007) 1.28

Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A (2015) 1.27

Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation. J Infect Dis (2013) 1.26

Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. Biomed Res Int (2015) 1.25

New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J Hematol Oncol (2009) 1.24

Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis (2009) 1.20

Multiple epitopes from the Mycobacterium tuberculosis ESAT-6 antigen are recognized by antigen-specific human T cell lines. Clin Infect Dis (2000) 1.20

Prospects for TIM3-Targeted Antitumor Immunotherapy. Cancer Res (2011) 1.17

Interleukin-6 as a therapeutic target. Clin Cancer Res (2015) 1.17

Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials. Hum Vaccin Immunother (2013) 1.12

A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One (2013) 1.12

Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe (2011) 1.10

Cytokine levels correlate with a radiologic score in active pulmonary tuberculosis. Am J Respir Crit Care Med (1999) 1.06

Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. PLoS One (2011) 1.05

Interception of host angiogenic signalling limits mycobacterial growth. Nature (2014) 1.04

Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. Proc Natl Acad Sci U S A (2015) 1.04

Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir. J Infect Dis (2015) 1.04

The Tim3-galectin 9 pathway induces antibacterial activity in human macrophages infected with Mycobacterium tuberculosis. J Immunol (2012) 1.02

Valproic acid increases formation of reactive oxygen species and induces apoptosis in postimplantation embryos: a role for oxidative stress in valproic acid-induced neural tube defects. Mol Pharmacol (2011) 1.02

Pulmonary impairment after tuberculosis and its contribution to TB burden. BMC Public Health (2010) 1.02

Towards host-directed therapies for tuberculosis. Nat Rev Drug Discov (2015) 1.01

Eicosanoids in inflammation and cancer: the role of COX-2. Expert Rev Clin Immunol (2009) 1.00

The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin Ther Targets (2011) 1.00

Histone deacetylase inhibitors: development as cancer therapy. Novartis Found Symp (2004) 0.99

CD40 ligand and interferon-γ induce an antimicrobial response against Mycobacterium tuberculosis in human monocytes. Immunology (2013) 0.99

Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev (1992) 0.99

Cytotoxic therapy for severe swine flu A/H1N1. Lancet (2010) 0.98

Programmed death ligand 1 is over-expressed by neutrophils in the blood of patients with active tuberculosis. Eur J Immunol (2011) 0.97

Foxp3+ regulatory T cells among tuberculosis patients: impact on prognosis and restoration of antigen specific IFN-γ producing T cells. PLoS One (2012) 0.97

HIV-1 tuberculosis-associated immune reconstitution inflammatory syndrome. Semin Immunopathol (2015) 0.97

The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy. Immune Netw (2014) 0.96

IL-32 is a molecular marker of a host defense network in human tuberculosis. Sci Transl Med (2014) 0.95

Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic killing of Mycobacterium tuberculosis through inositol depletion. EMBO Mol Med (2014) 0.94

Simvastatin increases the in vivo activity of the first-line tuberculosis regimen. J Antimicrob Chemother (2014) 0.94

High-dose vitamin D3 in adults with pulmonary tuberculosis: a double-blind randomized controlled trial. Am J Clin Nutr (2015) 0.93

The IL-13/IL-4Rα axis is involved in tuberculosis-associated pathology. J Pathol (2014) 0.93

Significant Effects of Oral Phenylbutyrate and Vitamin D3 Adjunctive Therapy in Pulmonary Tuberculosis: A Randomized Controlled Trial. PLoS One (2015) 0.93